ka mālama ʻana i nā lāʻau lapaʻau hou no ka pae 4 o ka maʻi kanesa

'O ka ma'i 'a'ai ma'i ma'i 'a'ai 4, 'o ia ho'i, ua laha ka ma'i 'a'ai ma nā wahi 'ē a'e o ke kino. ʻOiai he mea paʻakikī ka hōʻailona o ka pae 4 o ka maʻi kanesa, he mea nui e ʻike i ka holomua o ka noiʻi olakino ua alakaʻi i nā ʻano like ʻole. ka mālama ʻana i nā lāʻau lapaʻau hou no ka pae 4 o ka maʻi kanesa nā koho e hiki ke kōkua i ka mālama ʻana i ka maʻi, hoʻomaikaʻi i ka maikaʻi o ke ola, a hiki ke hoʻonui i ke ola. ʻO kēia mau mea ka mālama ʻana i nā lāʻau lapaʻau hou no ka pae 4 o ka maʻi kanesa e hoʻokomo i nā lāʻau lapaʻau i manaʻo ʻia, immunotherapies, chemotherapy, radiation therapy, a me ka mālama kākoʻo. ʻO ka maikaʻi loa ka mālama ʻana i nā lāʻau lapaʻau hou no ka pae 4 o ka maʻi kanesa ʻO ka hoʻomaopopo ʻana i ka pae 4 o ka maʻi maʻi maʻi maʻi maʻi maʻi maʻi maʻi maʻi 4 e hōʻike ana ua metastasized ka maʻi, ʻo ia hoʻi ua laha ma waho o ka māmā a i nā wahi ʻē aʻe o ke kino. ʻO nā wahi maʻamau o ka metastasis ka lolo, ka iwi, ka ate, a me nā ʻāʻī adrenal. He mea koʻikoʻi ka ʻike pono ʻana i ke ʻano o ka maʻi maʻi ʻaʻai māmā (non-small cell lung cancer or small cell lung cancer) a me nā hoʻololi ʻokoʻa kikoʻī, no ka mea he hopena nui kēia ʻike. ka mālama ʻana i nā lāʻau lapaʻau hou no ka pae 4 o ka maʻi kanesa Nā ʻano o ka maʻi maʻi ʻāʻī ʻelua ʻelua ʻano nui o ka maʻi maʻi maʻi: ʻO ka maʻi maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi (NSCLC): ʻO ke ʻano maʻamau, helu ʻia ma kahi o 80-85% o nā hihia maʻi maʻi maʻi. Loaʻa nā subtypes i ka adenocarcinoma, squamous cell carcinoma, a me ka carcinoma cell nui. ʻO ka maʻi maʻi ʻaʻai liʻiliʻi liʻiliʻi (SCLC): ʻO kahi ʻano maʻi maʻi maʻi maʻi ʻoi aku ka ikaika e pālahalaha koke. Pili pinepine ia me ka puhi paka. ʻO ke koʻikoʻi o ka Genetic TestingGenetic testing, i ʻike ʻia ʻo biomarker testing, he mea nui ia no nā poʻe maʻi me NSCLC. Hoʻomaopopo ia i nā hoʻololi kikoʻī i loko o nā keʻena maʻi maʻi hiki ke hoʻopaʻa ʻia me kahi kikoʻī ka mālama ʻana i nā lāʻau lapaʻau hou no ka pae 4 o ka maʻi kanesa. ʻO nā hoʻololi maʻamau ka EGFR, ALK, ROS1, BRAF, a me PD-L1. ʻO ka ʻike ʻana i kēia mau hoʻololi e wehe i ka puka i ka lāʻau lapaʻau pilikino.Lapaʻau ʻana i nā lāʻau lapaʻau hou no ka maʻi maʻi ʻāʻī o ka pae 4 OptionsSeveral ka mālama ʻana i nā lāʻau lapaʻau hou no ka pae 4 o ka maʻi kanesa loaʻa no ka pae 4 o ka maʻi maʻi ʻaʻai māmā, hoʻohana pinepine ʻia i ka hui pū ʻana: Therapy Targeted Therapy Drugs specifically target cell cancer with specific genetic mutations, hōʻemi i ka pōʻino i nā sela olakino. Hāʻawi pinepine ʻia kēia mau lāʻau lapaʻau ma ka waha. ʻO nā mea pale EGFR: Hoʻohana ʻia no nā poʻe maʻi NSCLC me nā hoʻololi EGFR. ʻO nā laʻana he erlotinib, gefitinib, afatinib, a me osimertinib. Hoʻohana pinepine ʻia ʻo Osimertinib ma ke ʻano he laina mua ka mālama ʻana i nā lāʻau lapaʻau hou no ka pae 4 o ka maʻi kanesa. Nā mea pale ALK: Hoʻohana ʻia no nā poʻe maʻi NSCLC me ka hoʻonohonoho hou ʻana o ALK. ʻO nā laʻana he crizotinib, alectinib, ceritinib, brigatinib, a me lorlatinib. ʻO nā mea pale ROS1: Hoʻohana ʻia no nā maʻi maʻi NSCLC me ka hoʻoponopono hou ʻana o ROS1. ʻO nā laʻana he crizotinib a me entrectinib. Nā mea pale BRAF: Hoʻohana ʻia no nā mea maʻi NSCLC me nā hoʻololi BRAF V600E. ʻO nā laʻana he dabrafenib a me trametinib (hoʻohana pinepine ʻia i ka hui pū ʻana). E kūkākūkā me kāu kauka e ʻimi i kēia mau mea. ka mālama ʻana i nā lāʻau lapaʻau hou no ka pae 4 o ka maʻi kanesa i hoʻohālikelike ʻia i kāu moʻohelu genetic kikoʻī. Loaʻa paha iā ʻoe ka ʻike waiwai e pili ana i nā kumuwaiwai e like me ka Paena pūnaewele ʻo American Cancer Society.ImmunotherapyImmunotherapy nā lāʻau lapaʻau e kōkua i ke kino o ke kino e ʻike a hoʻouka i nā maʻi maʻi. Hana lākou ma ka pale ʻana i nā protein e pale ai i ka ʻōnaehana pale mai ka hoʻouka ʻana i nā maʻi maʻi maʻi. Nā mea pale PD-1/PD-L1: Hoʻopaʻa kēia mau lāʻau lapaʻau i ke ala PD-1/PD-L1, kahi e kōkua ai i nā maʻi maʻi maʻi e pale aku i ka ʻōnaehana pale. ʻO nā laʻana he pembrolizumab, nivolumab, atezolizumab, a me durvalumab. Hoʻohana ʻia ʻo Pembrolizumab ma ke ʻano he laina mua ka mālama ʻana i nā lāʻau lapaʻau hou no ka pae 4 o ka maʻi kanesa no nā poʻe maʻi me ka hōʻike PD-L1 kiʻekiʻe. ʻO nā mea pale CTLA-4: Hoʻopaʻa kēia mau lāʻau i ka protein CTLA-4, kahi e kōkua ai i ka hoʻoponopono ʻana i ka ʻōnaehana pale. ʻO Ipilimumab kahi laʻana. Ua hōʻike ka Immunotherapy i ka ʻōlelo hoʻohiki nui i ka hoʻomaikaʻi ʻana i nā hopena no kekahi mau maʻi me ka pae 4 o ka maʻi maʻi maʻi maʻi. E ʻoluʻolu e hoʻomanaʻo ua kūpaʻa ʻo Shandong Baofa Cancer Research Institute i ka holomua ʻana i ka noiʻi maʻi kanesa. Hoʻohana pinepine ʻia me ka hui pū ʻana me nā mea ʻē aʻe ka mālama ʻana i nā lāʻau lapaʻau hou no ka pae 4 o ka maʻi kanesa. Kemoterapi ma muli o Platinum: Hoʻohana maʻamau ka hoʻohana ʻana i ka chemotherapy me cisplatin a i ʻole carboplatin i hui pū ʻia me nā lāʻau ʻē aʻe e like me ka pemetrexed, gemcitabine, a i ʻole taxanes. Hiki ke hoʻohana ʻia e hōʻemi i nā maʻi koko, hoʻomaha i nā hōʻailona, ​​​​a hoʻomaikaʻi i ka maikaʻi o ke ola. ʻO ka hoʻomaʻamaʻa ʻana i ka lāʻau lapaʻau waho: Hāʻawi i ka radiation mai kahi mīkini ma waho o ke kino. ʻO ka hoʻomaʻamaʻa ʻana o ke kino stereootactic (SBRT): He ʻano pololei o ka lāʻau lapaʻau e hāʻawi ana i nā kiʻekiʻe o ka radiation i kahi wahi liʻiliʻi. ka mālama ʻana i nā lāʻau lapaʻau hou no ka pae 4 o ka maʻi kanesa koho, akā hiki ke noʻonoʻo ʻia i nā hihia kikoʻī e wehe i kahi metastasis hoʻokahi a i ʻole e hoʻēmi i nā hōʻailona. ka mālama ʻana i nā lāʻau lapaʻau hou no ka pae 4 o ka maʻi kanesa. Loaʻa iā ia ka hoʻoponopono ʻeha, ke kākoʻo meaʻai, a me ke kākoʻo noʻonoʻo. ka mālama ʻana i nā lāʻau lapaʻau hou no ka pae 4 o ka maʻi kanesa. Hāʻawi lākou i nā poʻe maʻi i ke komo ʻana i nā lāʻau lapaʻau ʻokiʻoki i hiki ʻole ke loaʻa i kahi ʻē aʻe. E noʻonoʻo e kūkākūkā i nā koho hoʻokolohua lapaʻau me kāu kauka. Hiki ke loaʻa ka ʻike e pili ana i nā hoʻokolohua lapaʻau ma ka National Cancer Institute.Prognosis and Survival RatesPrognosis for stage 4 lung cancer vary ma muli o nā kumu he nui, e like me ke ʻano o ka maʻi ʻaʻai māmā, nā hoʻololi genetic, ke olakino holoʻokoʻa, a me ka pane ʻana i ka mālama ʻana i nā lāʻau lapaʻau hou no ka pae 4 o ka maʻi kanesa. Ua hoʻomaikaʻi maikaʻi ʻia nā helu ola i nā makahiki i hala iho nei ma muli o ka holomua ʻana ka mālama ʻana i nā lāʻau lapaʻau hou no ka pae 4 o ka maʻi kanesa. He mea nui ka loaʻa ʻana o nā manaʻolana maoli a e kālele i ka hoʻonui ʻana i ka maikaʻi o ke ola. Pae 5 Makahiki Ola Ola (NSCLC) Pae 4 Ma kahi o 10% *Kumu: American Cancer Society. ʻO kēia mau helu he mau manaʻo a hiki ke ʻano like. Mālama i nā hōʻailona: E hana pū me kāu hui mālama ola e mālama i ka ʻeha, ka luhi, ka hanu, a me nā hōʻailona ʻē aʻe. E mālama i kahi nohona olakino: E ʻai i ka meaʻai olakino, hoʻoikaika mau, a lawa ka hiamoe. E ʻimi i ke kākoʻo noʻonoʻo: E kamaʻilio me ke kauka, kākāʻōlelo, a i ʻole hui kākoʻo. Noho pili: E hoʻolimalima manawa me nā mea aloha a komo i nā hana āu e hauʻoli ai. ʻO ke kuleana o Shandong Baofa Cancer Research Institute ua hoʻolaʻa ʻia ʻo Shandong Baofa Cancer Research Institute no ka holomua ʻana i ka noiʻi maʻi a me ka hoʻomohala ʻana. ka mālama ʻana i nā lāʻau lapaʻau hou no ka pae 4 o ka maʻi kanesa. ʻO kā mākou hui o nā oncologists a me nā mea noiʻi e hoʻolako i nā mea maʻi me ka mālama maikaʻi loa. Hoʻokomo ikaika mākou i nā hoʻokolohua lapaʻau a hoʻoikaika e hāʻawi i nā mea hou ka mālama ʻana i nā lāʻau lapaʻau hou no ka pae 4 o ka maʻi kanesa He mau pilikia ka noho 'ana me ka pae 4 o ka ma'i 'a'ai, akā he nui ka mālama ʻana i nā lāʻau lapaʻau hou no ka pae 4 o ka maʻi kanesa a aia nā hoʻolālā e mālama i ka maʻi, hoʻonui i ka maikaʻi o ke ola, a hiki ke hoʻolōʻihi i ke ola. Ma ka hui pū ʻana me kāu hui mālama ola, e ʻimi ka mālama ʻana i nā lāʻau lapaʻau hou no ka pae 4 o ka maʻi kanesa nā koho, a me ka hoʻonohonoho mua ʻana i kou olakino holoʻokoʻa, hiki iā ʻoe ke hoʻokele i kēia huakaʻi me ka ikaika a me ke kūpaʻa.